Core Viewpoint - The legal opinion letter issued by King & Wood Mallesons confirms that Shanghai Kehua Bio-engineering Co., Ltd. can proceed with the repurchase of its convertible bonds under specific conditions outlined in the relevant regulations and the offering prospectus [1][9]. Group 1: Legal Framework and Compliance - The legal opinion is based on the Company Law, Securities Law, and relevant regulations, ensuring that the facts presented are true, accurate, and complete [2][3]. - King & Wood Mallesons has conducted thorough verification of the documents related to the bond repurchase, ensuring compliance with legal standards [2][3]. Group 2: Convertible Bond Issuance and Approval - The company received approval from the China Securities Regulatory Commission (CSRC) to issue convertible bonds totaling 738 million yuan, with a maturity of six years [6][7]. - The bonds were listed on the Shenzhen Stock Exchange on August 20, 2020, under the name "Kehua Convertible Bonds" [7]. Group 3: Repurchase Conditions - The offering prospectus stipulates that bondholders can sell their bonds back to the company if the stock price falls below 70% of the conversion price for 30 consecutive trading days during the last two interest periods [8][9]. - The company’s stock price was below the specified threshold of 14.45 yuan per share for the required period, thus triggering the repurchase conditions [8][9]. Group 4: Conclusion and Recommendations - The legal opinion concludes that the company can repurchase the convertible bonds as per the established conditions, provided that the repurchase announcement and results are properly disclosed [9].
科华生物: 北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司可转换公司债券回售的法律意见书